Global Precision Oncology Market - Trends and Growth Opportunities

Global Precision Oncology Market - Trends and Growth Opportunities

The procedure for accurately identifying a biomarker correlation based on a patient’s genetic makeup is complex and relies on the expertise and knowledge of an oncologist, decision-support scientist, or other healthcare professional involved in the matching process. Precision oncology aims to provide oncologists with diagnosis, prognosis, and treatment tools to tailor the treatment according to patients’ genetic makeup.

Acquiring, storing, and processing high-quality biomaterials and collecting organized clinical information with longitudinal data sets is a challenge. Consent and securely sharing sensitive data with analytical platforms within and outside healthcare organizations are practical problems when dealing with patient data. Emerging technologies such as AI, ML, robotics, and big data-based multi-omics tools are enabling and improving the precision and development of targeted treatments.

Extensive tumor profiling is required for the identification of accurate genetic biomarkers and actionable targets. Accurate diagnosis is crucial for implementing personalized treatment for patients. It is crucial to identify specific biomarkers that can predict both the response to treatment and the occurrence of adverse effects in patients, to determine the subpopulation that would benefit from a particular therapy. This helps to account for genetic predisposition.

Precision oncology has changed clinical trial design, resulting in precision diagnostics-based studies such as umbrella trials and basket trials. These studies treat patients based on their oncogenic driver aberration, not their cancer kind. The most recent type is N-of-1 studies, often called patient-centered trials, which assess patient-specific therapy combinations.

Precision oncology uses careful monitoring to assess tumor response to therapy and change therapeutic actions if drug resistance is anticipated. Post-treatment molecular testing may detect resistance mutations. Noninvasive disease burden monitoring using plasma circulating tumor cell cDNA analysis is a breakthrough.

This study highlights current technological trends and emphasizes the interdisciplinary efforts underway to ensure that a greater number of cancer patients can benefit from precision oncology soon. The study also highlights some of the key market drivers and restraints, partnerships, and present and future market trends that affect the growth of the market. Industry use cases will provide brief insights into some of the game-changing participants who are working toward developing disruptive technologies and drugs for precision oncology. The study will provide emerging growth opportunities for the market based on clinical need, use cases, business models, preventive care, market access strategies, and technology trends. Show more